Our data suggest that in this murine model, splenic erythropoiesis may influence stromal cell therapy, and that higher levels of marrow engraftment may be necessary to obtain a clinically significant effect.
The hematopoietic microenvironment plays an important role in the support and regulation of hematopoiesis. Stromal cells, one component of this environment, are required for support of long-term hematopoiesis in vitro. 1 These cells are an important source of cytokines, adhesion molecules and extracellular matrix components. [2] [3] [4] The importance of a normal hematopoietic microenvironment is illustrated by the Sl/Sl d mouse. These mice offer a model of abnormal hematopoiesis due to defective production of the cytokine stem cell factor (SCF) by marrow stromal cells. 5, 6 In addition to macrocytic anemia, Sl/Sl d mice experience a deficiency of tissue mast cells, as well as fertility and pigmentation defects. These defects have been attributed to abnormal microenvironments for these cell lineages. 7 The anemia of Sl/Sl d mice is not corrected by transplantation of hematopoietic cells, 8 unlike the complementary mutant W/W v mouse, which responds to marrow transplantation. 9, 10 The W/W v mouse has a similar disease phenotype, but in contrast is attributed to a defect in the receptor for SCF, c-kit. 7 The anemia in Sl/Sl d mice responds to transplantation of splenic tissue, which provides an intact normal hematopoietic microenvironment. In vitro studies by Dexter 12 Stromal cells from these mice are incapable of producing the membrane-bound isoform of SCF. 5, 6 It is feasible that transplantation of stromal cells with normal SCF expression into Sl/Sl d mice may provide an attractive and convincing model for treating an abnormal hematopoietic microenvironment.
Stromal cell transplantation has been achieved using non-hematopoietic mesenchymal cells derived from longterm bone marrow cultures, 13 as well as stromal cell lines. 14 Anklesaria et al 15 showed that infusion of a transformed stromal cell line into irradiated and splenectomized Sl/Sl d mice could partially correct their anemia. The aim of our study is to extend this observation by transplanting normal stromal cells, derived from long-term bone marrow cultures, into unconditioned Sl/Sl d recipients as a model for human cell therapy. ) (Jackson Laboratory, Bar Harbor, ME, USA). The cells were maintained in ␣-medium (Gibco BRL, Burlington, ON, Canada) with 10% horse serum, 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA), 10 Ϫ6 m hydrocortisone (Sigma, St Louis, MO, USA), l-glutamine, and antibiotics (Gibco BRL) and incubated at 37°C in 5% CO 2 . Stromal cells were used for transplantation after five or six serial passages in vitro. A sex-mismatch transplant model was employed, in which male donor stromal cells were infused into unconditioned female Sl/Sl d recipient mice according to a local IRB-approved protocol. The cells were injected intravenously via the lateral tail vein, and recipients were monitored for changes in hematological parameters over 4 months until death post transplant.
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Materials and methods
Stromal cell transplantation
Stromal cell phenotype
Expression of Mac-1 and CD45 on stromal cells was assayed by flow cytometry using a FACScan analyzer and CELLQuest software (Becton Dickinson, Mississauga, ON, Canada). Stromal cells were washed with phosphate buffered saline (PBS) and incubated with either FITC-conjugated rat anti-mouse Mac-1 antibody (Serotec, Oxford, UK) or FITC-conjugated rat anti-mouse CD45 antibody (Pharmingen, San Diego, CA, USA) at room temperature. Appropriate isotype antibodies were used as controls. Analyses were done in triplicate on 10 000-20 000 cells. To assess collagen IV expression, stromal cells were grown on Lab-Tek chamber slides and fixed with paraformaldehyde prior to staining (Nalge Nunc, Naperville, IL, USA). Cells were incubated with rabbit anti-mouse collagen IV antibody (Biodesign, Kennebunk, ME, USA) followed by FITC-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories) at room temperature. To assess both positive and negative staining cells, a DAPI counterstain was used (4′,6-diamidine-2′-phenylindole dihydrochloride) (Oncor, Gaithersburg, MD, USA). Collagen IV-positive stromal cells were viewed using a fluorescence microscope. Analyses were done in duplicate on 200-700 cells.
Engraftment of male stromal cells into female recipients
Fluorescence in situ hybridization (FISH) was used to identify the frequency of male cells in the marrow of female recipient mice. Bone marrow suspensions were fixed in acetic acid:methanol and cells dropped on to microscope slides. The slides were treated with 100 g/ml RNase, washed and dehydrated before denaturation at 75°C, in 50% formamide in 2 ϫ SSC. A biotinylated Y chromosome paint (Cambio, Cambridge, UK) was mixed with Hybrisol VI (Oncor) and denatured at 75°C, prior to hybridization with the slides overnight at 37°C. The hybridized probe was detected by incubation with FITC-labeled avidin, followed by an amplification step involving incubation with anti-avidin antibody and another round of FITC-avidin (Oncor). The slides were counterstained with DAPI and propidium iodide (PI). To determine the percentage of donor cells, 1000 to 1500 nuclei per slide were counted using a fluorescence microscope.
Presence of donor cells in spleen samples was determined using a duplex PCR method. This allowed identification of a 292 bp portion of the testis determining region on the Y chromosome (Tdy), 16 along with a 147 bp portion of SCF exon 5, a region unaffected by the Sl d mutation, as an internal positive control. 12, 17 The oligonucleotide primers used had the following sequences: TDY1 5′-GACTG GTGACAATTGTCTAG-3′, TDY2 5′-TAAAATGCCACT CCTCTGTG-3′, SCF1 5′-AAAGAATCTCCGAAGAG GCC-3′, SCF2 5′-CTCGGGACCTAATGTTGAAG-3′. PCR involved 30 cycles at 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min. The reaction mixture consisted of 500 ng sample DNA, 4 ng/l of each TDY primer, 2 ng/l of each SCF primer, 1. 
Hematological parameters
Erythrocyte indices were monitored on a monthly basis from peripheral blood samples obtained from the retroorbital sinus while mice were anesthetized by inhalation of isoflurane (Schein Pharmaceutical, Etobicoke, ON, Canada). Littermates of Sl/Sl d mice, which did not exhibit the mutant phenotype, were used as controls for hematological parameters. Samples were processed by a CELL-DYN 3000 automated blood cell analyzer to determine erythrocyte (RBC) number, mean cell volume (MCV), hemoglobin (HGB), and leukocyte count (WBC). The mean erythrocyte size distribution was also assessed for each treatment group, and statistical analysis performed using a Wilcoxon rank sum nonparametric test.
Marrow hematopoietic progenitor levels were determined by methlycellulose colony assays. 18 Briefly, 1 ϫ 10 5 femoral bone marrow cells were cultured in ␣-medium containing 1% methylcellulose (StemCell Technologies, Vancouver, BC), 30% fetal bovine serum, 1% BSA (Boehringer Mannheim, Laval, QC, Canada), 10 Ϫ4 2-mercaptoethanol (Sigma), 14% pokeweed mitogen-spleen conditioned medium (Gibco BRL), 2 U/ml recombinant human erythropoietin (Ortho Pharmaceutical, Raritan, NJ, USA), l-glutamine and antibiotics and incubated at 37°C in an atmosphere of 5% CO 2 . Colony numbers (BFU-E, CFU-E, CFU-GM) were counted between days 8 and 11 of culture. Statistical comparisons were done using a Student's t-test.
Results
Serial passage in vitro was performed to increase the number of stromal cells, as well as deplete contaminating hematopoietic cells. The phenotype of stromal cells in the adher- (Table 2 ). However, recipients of higher doses of cells (approximately 2.5 million per mouse) did have appreciable engraftment in the marrow. Donor cells were found in similar ranges of frequencies in both stromal transplant groups, with levels up to 1% of the total marrow nucleated cell population. During the course of the study, erythropoiesis was monitored after stromal cell transplantation including the assessment of erythroid progenitor levels in the bone marrow at death. There was a significant difference in marrow erythroid progenitors in mice receiving 2. . Levels of CFU-GM were not significantly different between these two groups (P = 0.087). Contamination of the stromal grafts by hematopoietic cells is not a likely source of the increased number of erythroid progenitors. Because hematopoiesis was assessed in recipient mice 4 months after transplant, only contamination by stem cells could account for this increase. Hematopoietic contamination of the stromal graft is at a low level (Table 1) , and thus not likely to contain a significant number of stem cells, which would have an even lower frequency. We have shown that 3 ϫ 10 6 culture-derived stromal cells had no detectable CFU-S. 20 In addition, whole marrow from W/W v donors did not engraft well in unconditioned Sl/Sl d mice ( can be discounted as a source of the increase in erythroid progenitors. The mice were monitored to determine whether there was any effect on mature erythrocytes. No change in red cell indices (RBC number, MCV, hemoglobin) was observed during the course of the experiment, nor were WBC levels affected, for all stromal cell dose groups (Table 4) . A correction in the macrocytic anemia would require an increase in erythrocyte number and a reduction in the mean cell volume, however both indices remained unchanged. Transplantation of W/W v whole marrow also had no effect on erythrocyte parameters, consistent with previous studies. 8 Analysis of the mean RBC size distribution was performed for recipients receiving the higher dose of stromal cells to determine if more subtle changes in erythropoiesis were occurring that were not reflected in the MCV (Figure 2) . Although a slight shift towards smaller erythrocytes in recipients of W/W v stroma was noted, the overall distribution was not significantly different from the erythrocytes of Sl/Sl d stromal cell recipients (P = 0.195).
Discussion
The ability of stromal cells to engraft in unconditioned recipients has important implications for the clinical applications that do not require myeloablation. The present study demonstrates stromal engraftment in the marrow of unconditioned Sl/Sl d mice. Although engraftment did not exceed 1% of the total nucleated cell population, it should be noted that endogenous stromal cells constitute only a minor population and thus, the donor cells may represent a doubling of the original number. 21, 22 Donor cell engraftment must be due to non-hematopoietic stromal cells because hematopoietic cell contamination was negligible. Although donor Table 4 Erythrocyte parameters in peripheral blood of recipients of high doses of stromal cells (approximately 2.5 million cells) analysis by FISH was limited to detection of male cells in the whole marrow, the levels found were similar to those of previous studies from our laboratory. 19 We have also shown that donor cells present in whole marrow preparations are detected by FISH at higher levels among the cultured stromal cells derived from the same transplant recipients. 19 Although the present study did not analyze CFU-F chimerism, Anklesaria et al 15 showed that over half of the CFU-F were donor-derived after transplantation of a stromal cell line.
While hematopoietic cell transplantation is unable to correct the macrocytic anemia of Sl/Sl d mice, 8 the transplantation of a normal hematopoietic microenvironment in the form of an intact spleen can treat these mice effectively. 23 Thus, it could be inferred that infusion of stromal cells with normal SCF expression into Sl/Sl d mice may alleviate the anemia, in contrast to Sl/Sl d stromal cells which support in vitro hematopoiesis poorly. 11 Anklesaria et al 15 showed that infusion of a transformed stromal cell line into irradiated and splenectomized Sl/Sl d mice could yield a small improvement in erythropoiesis. The aim of our study was to investigate the role of non-transformed marrow stromal cells in correcting the disorder in unconditioned recipients. 24 The authors speculate that the defect in these mice may arise at the BFU-E/CFU-E transition. Other studies have also shown the importance of SCF in regulating early erythroid progenitors. The receptor for SCF has been identified on erythroid progenitors, 25 and marrow progenitors expressing this receptor differentiate into BFU-E in response to SCF. 26 Also, injection of recombinant SCF into baboons increases the number of primitive hematopoietic progenitors, including BFU-E. 27 The limited biological effect of stromal cell transplantation in our model may be due to preponderance of erythropoiesis in the spleen and contrasts with the marrowbased erythropoiesis in humans. Transplantation of marrow cells to the spleen results in predominantly erythroid differentiation in the mouse, 29 and in response to phenylhydrazine-induce anemia, most of the erythroid expansion occurs in the spleen and is dependent on SCF/c-kit interaction. 30 Most importantly, the spleen has been shown to be a target for correction of the Sl/Sl d anemia, as demonstrated by the imporvement in erythropoiesis following transplantation of a normal spleen. 23 In the study by Anklesaria et al, 15 the recipient mice were irradiated and splenectomized prior to stromal cell infusion. Irradiation may have purturbed endogenous marrow hematopoiesis sufficiently to allow transplanted stromal cells to have an effect, while splenectomy effectively removed a competing site of erythropoiesis. Our study used unconditioned host mice with intact splenic erythropoiesis. We failed to detect splenic engraftment of donor stromal cells, although there was marrow engraftment. It may be that the change in the marrow erythroid progenitor level we observed was insufficient to overcome ongoing abnormal erythropoiesis in the spleen. However, this limitation in the murine model is not relevant to the clinical application of stromal cell therapy because the spleen is not normally a site of human hematopoiesis.
Although we observed an increase in marrow erythroid progenitors, the inability to correct the anemia suggests that higher levels of stromal engraftment may be required. A major improvement in erythropoiesis may require the presence of a significant amount of normal hematopoietic microenvironment. Kapur et al 31 has shown that breeding a transgenic mouse expressing a membrane-restricted SCF cDNA, on to a Sl/Sl d background resulted in improved erythrocyte production compared with unmanipulated Sl/Sl d mice. In addition, the injection of recombinant SCF at pharmacological doses also corrected the anemia, albeit transiently. 32 Anklesaria et al 15 Our data, and the studies of others, indicate that stromal cell infusion can influence host hematopoiesis 14, 15, 33, 34 and suggest that this approach has possible application in cell and/or gene therapy. 35, 36 The use of stromal cells has the added dimension of extensive transdifferentiation potential to osteoblasts, chondroblasts, 37, 38 fibroblasts, 39 muscle, 40 astrocytes, 41 and neurons. 42 Also, stromal cells could be used as a vehicle for gene therapy to introduce defective or missing genes. 43 Based on our murine model, our studies
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indicate that for stromal cell transplantation to become a feasible form of cell therapy further studies are required, particulary novel approaches that enhance stromal marrow engraftment in unconditioned recipients.
